Lysogene - Meeting Notice of the Annual Ordinary and Extraordinary General Meeting to be held on 25 June 2021

PARIS--()--Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 25, 2021 at 09:00 am (CEST), at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008), France.

The preliminary meeting notice which is also a convening notice, including the agenda and the text of the proposed resolutions, was published in the French bulletin of compulsory legal notices (Bulletin des Annonces Légales Obligatoires – BALO) dated May 19, 2021. A copy is available on the Company’s website https://www.lysogene.com/annual-meetings/.

The Shareholders’ Meeting documents and the voting form will be made available to Shareholders under the terms and conditions specified by current French regulations.

The detailed procedures for participating to the meeting and send written questions are available in the meeting notice n° 2101874, which was published in the BALO (Journal Officiel) n° 60 dated May 19, 2021.

About Lysogene
Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

Contacts

Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99

Contacts

Stéphane Durant des Aulnois
Chief Financial Officer
stephane.durant-des-aulnois@lysogene.com
+ 33 1 41 43 03 99